Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NBI's Sales Exceeded Industry Average for Five Consecutive Years: Dr T. Heil
June 8, 2009
- Towa: New Products Listed in 2008 Drive Sales
June 8, 2009
- Takeda Licenses Hib Vaccine from Novartis
June 8, 2009
- Nichi-Iko to Create Joint Venture with Mitani Sangyo to Manufacture Raw Materials for Generics
June 8, 2009
- Daiichi Sankyo Revises Net Loss from ¥335.8 Bil. to ¥215.5 Bil.
June 8, 2009
- Korosho to Call For Stricter Adherence to Ryotan-kisoku for Use of More Generics
June 8, 2009
- Co-DIO, Ecard Ranked No. 1 and 2 on Both GP and HP Markets
June 8, 2009
- Rohto: Sales Up 16th Year in a Row
June 8, 2009
- Yoshiki Bessho of Suzuken Elected New FJPWA President
June 8, 2009
- Taisho Launches RiUP X5 Hair Growth Stimulator for Men
June 8, 2009
- CMIC: Semi-Annual Sales Up 14.4% Driven by CRO Business
June 8, 2009
- Switch OTC Drugs Based on Vidarabine Recommended for Approval
June 8, 2009
- EPS: Strong CRO Business Pushes Up Sales 11.6%
June 8, 2009
- Otsuka HD: Sales of Healthcare Products Up to ¥676.7 Bil.
June 1, 2009
- GENERICS NEWS IN BRIEF
June 1, 2009
- Zeria: Mid-Term Sales Target Down to ¥73 Bil.
June 1, 2009
- Quintiles Named Most Favored CRO in 2 Independent Surveys
June 1, 2009
- ASKA: Profits Plummet with Flat Sales
June 1, 2009
- 60% of Patients Prefer In-House Prescriptions at Sanjou Hospital
June 1, 2009
- Seikagaku: Sales of Artz Up in Japan, China
June 1, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…